Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Down 57.0% in October

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 6,500 shares, a decrease of 57.0% from the October 15th total of 15,100 shares. Based on an average daily volume of 127,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.1% of the company’s stock are short sold.

Estrella Immunopharma Stock Performance

Shares of ESLA remained flat at $0.84 during mid-day trading on Thursday. 3,930 shares of the stock traded hands, compared to its average volume of 78,063. The firm has a market capitalization of $30.40 million, a PE ratio of -0.42 and a beta of 0.24. The firm’s fifty day simple moving average is $0.93 and its two-hundred day simple moving average is $1.10. Estrella Immunopharma has a 52 week low of $0.63 and a 52 week high of $3.23.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings data on Friday, September 27th. The company reported ($0.13) EPS for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.